Do you have a passion for making your voice heard and empowering others? Do you want to make a difference in the lives of people with ALS? The 16,000+ advocates for The ALS Association are people living with ALS, family members, friends, caregivers, researchers, scientists, and healthcare professionals who are ready to see a world without ALS.
Lauren Sciences LLC, a private biotechnology company in New York, N.Y., recently received a third grant from The ALS Association to support the continued development of LAUR-301, Lauren Sciences’ novel V-Smart Nanomedicine designed specifically for ALS.
Today, we are happy to be joined by ALS clinician scientist Dr. Peter Creigh from the University of Rochester in Rochester, N.Y., the recipient of the 2018 Clinician Research Training Fellowship in ALS Research. The fellowship is given by The ALS Association, in partnership with the American Academy of Neurology (AAN).
The ALS Association is happy to continue our tradition of supporting bright, young scientists in ALS research through our Milton Safenowitz Postdoctoral Fellowship Program. These awards encourage young scientists to enter and, importantly, to remain in the ALS field.
The ALS Association is committed to helping improve clinical trial design, in order to increase trial efficiency that will more quickly lead to effective therapeutics. We awarded Dr. David Ennist and colleagues at Origent Data Sciences, Inc. two grants to support research exploring how machine learning algorithms, a type of computational tool, can optimize clinical trial design. Dr. Ennist’s work, recently published in the journal Annals of Clinical Trial and Translational Neurology, looks closely at optimizing patient randomization into clinical trials.
On December 7, 2017, Calaneet Balas began her role as president and CEO for The ALS Association. This article is the first in a new monthly blog series called "Calaneet’s Corner." Each column will provide you with a mission update and let you hear directly from Calaneet. Our first column goes behind the scenes to get to know Calaneet.
Held March 20-21, the annual ALS Advocacy Fly-In was very successful, as The ALS Association’s executives, staff, and board members acted boldly to fight for a cure for ALS. On March 20, Fly-In attendees heard presentations from numerous speakers, including Mark Vieth from CRD Associates, Dr. Steve Landers from the Visiting Nurse Association Health Group, Inc., and leaders from The ALS Association’s Iowa and Greater Philadelphia chapters.
UPDATE: As of March 14, 2019, enrollment for the CENTAUR Phase II clinical trial has been completed. The CENTAUR phase II clinical drug trial, sponsored by Amylyx Pharmaceuticals and funded by ALS Ice Bucket Challenge donations, began an open-label extension, giving people with ALS who completed their trial period an opportunity to continue taking the drug, AMX0035.
People living with ALS eventually lose the ability to speak. That means that preserving channels of communication is an important component of enhancing quality of life. The ALS Association - DC/MD/VA Chapter took this to heart when they initiated The Esther Lerner Brenner ALS Assistive Technology Lab in Maryland, which is designed to help people living with ALS communicate effectively for as long as possible.
The ALS Association is happy to continue our tradition of supporting bright, young scientists in ALS research through our Milton Safenowitz Postdoctoral Fellowship Program. These awards encourage young scientists to enter and, importantly, to remain in the ALS field. Today, we sit down with Dr. Yue Li from Scripps Research Institute – Florida to learn about his important research project studying how specific RNA-protein interactions contribute to ALS disease.